Dato-DXd
Genitourinary Cancers
TROPION-Urothelial03: A phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma
Galsky MD, Drakaki A, Basu A, et al.
Future Oncol. 2026;22(12):1387-1396. doi: 10.1080/14796694.2026.2663956.
Edoxaban
Cardiovascular - AF
Association of edoxaban pharmacokinetics with bleeding in older patients with atrial fibrillation treated with low-dose edoxaban: A post hoc analysis of a randomized controlled trial.
Okumura K, Akao M, Fukuzawa M, Igawa Y, Hayashi T, Yamashita T.
J Am Heart Assoc. 2026;15(10):e042950. doi: 10.1161/JAHA.125.042950.
T-DXd
Gastric Cancer
Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study
Narita Y, Kawakami H, Nakanishi K, et al.
Jpn J Clin Oncol. 2026;56(5):538-545. doi: 10.1093/jjco/hyaf216.
T-DXd
Gynecologic Cancers
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses
Lee JY, Oaknin A, Manso L, et al.
J Gynecol Oncol. 2026;37(3):e65. doi: 10.3802/jgo.2026.37.e65.
Dato-DXd
Breast Cancer
Datopotamab deruxtecan in Chinese patients with heavily pretreated advanced or metastatic triple-negative breast cancer in the phase I/II TROPION-PanTumor02 study
Wang T, Sun Y, Chen W, et al.
Transl Breast Cancer Res. 2026;7:11. doi: 10.21037/tbcr-2025-1-81.
Dato-DXd
Breast Cancer
Exposure-response analyses of datopotamab deruxtecan (Dato-DXd) in patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer
Tang Z, Lim K, Jiang Y, et al.
J Clin Pharmacol. 2026;66(4):e70188. doi: 10.1002/jcph.70188.
Other/Multi
Breast Cancer
ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage
Xie X, Lee J, Gi YJ, et al.
Br J Cancer. 2026. doi: 10.1038/s41416-026-03413-1.
Quizartinib
Hematology
Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First
Levis MJ, Erba HP, Montesinos P, et al.
Blood Adv. 2026;10(12):4144-4159. doi: 10.1182/bloodadvances.2025017738.
T-DXd
Tumor-agnostic
Post-hoc analysis of the Phase II DESTINY-PanTumor02 study: Local and central HER2 IHC concordance and trastuzumab deruxtecan efficacy by HER2 IHC status in HER2-Expressing solid tumors
Makker V, Lee JY, Oh DY, et al.
Clin Cancer Res. 2026. doi: 10.1158/1078-0432.CCR-25-4702.
Dato-DXd
Breast Cancer
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): A randomised, open-label, international, phase III trial
Dent R, Shao Z, Schmid P, et al.
Ann Oncol. 2026:S0923-7534(26)00130-4. doi: 10.1016/j.annonc.2026.03.008.